

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

27 Jun 2026

### Evaluation of the effect of CRSM-X7 herbal therapeutic supplement in the improving of symptoms of patients with COVID-19 hospitalized in the medical centers.

#### Protocol summary

##### Study aim

Determining the effect of CRSM-X7 as a herbal therapeutic supplement on the improvement of COVID-19 disease symptoms

##### Design

Clinical trial with parallel control group, non-blinded, randomized, phase 3-2 on 200 patients. For randomization Block method was used.

##### Settings and conduct

Using the formula for calculating the sample size, 200 patients referring to the medical centers of Baqiyatallah University of Medical Sciences will enter the study. 100 people in the intervention group receive a standard treatment regimen + herbal supplement, and 100 people in the comparison group receive only the same standard treatment regimen as the intervention group. There is no blinding in this study.

##### Participants/Inclusion and exclusion criteria

Inclusion criteria: Diagnosis of COVID-19 Age 18-65 Having informed and written consent to participate in the study Exclusion criteria: Disagreement of the physician directly responsible for the patient Pregnancy and breastfeeding Allergies to the drug elements Symptoms of gastrointestinal, liver or kidney disease Incidence of drug interactions Hypertension Having heart failure Do not take anticoagulants

##### Intervention groups

The intervention group includes patients with COVID-19 disease who receive the standard treatment regimen intervention + herbal therapeutic supplement of CRSM-X7. The comparison group includes patients with COVID-19 disease receiving standard dietary intervention.

##### Main outcome variables

Duration of hospitalization Fever The need for ICU admission Incidence of ARDS Intubation requirements Patient expire rate O2 saturation Body pain Cough

Olfactory Sense of taste computed tomography scan

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20210325050769N1**

Registration date: **2021-04-12, 1400/01/23**

Registration timing: **prospective**

Last update: **2021-04-12, 1400/01/23**

Update count: **0**

##### Registration date

2021-04-12, 1400/01/23

##### Registrant information

##### Name

Mohammad Heiat

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 21 8126 2072

##### Email address

mohamad.heiat@bmsu.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2021-04-19, 1400/01/30

##### Expected recruitment end date

2021-07-22, 1400/04/31

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

**Trial completion date**

empty

**Scientific title**

Evaluation of the effect of CRSM-X7 herbal therapeutic supplement in the improving of symptoms of patients with COVID-19 hospitalized in the medical centers.

**Public title**

Evaluation of the effect of herbal therapeutic supplements (Marsh - Mallow, Sweet violet, Malva sylvestris, Damask rose, Liquorice root) against corona disease

**Purpose**

Supportive

**Inclusion/Exclusion criteria****Inclusion criteria:**

Diagnosis of COVID-19 Age 18-65 Having informed and written consent to participate in the study

**Exclusion criteria:**

Disagreement of the physician directly responsible for the patient Pregnancy and breastfeeding Allergies to the drug elements Symptoms of gastrointestinal, liver or kidney disease Incidence of drug interactions Patient dissatisfaction to continue the project for any reason Inability of the patient to receive oral medication Hypertension Having heart failure Do not take anticoagulants (aspirin, Plavix, warfarin)

**Age**

From **18 years** old to **65 years** old

**Gender**

Both

**Phase**

2-3

**Groups that have been masked**

*No information*

**Sample size**

Target sample size: **200**

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

Randomization method: block, Randomization unit: individual Randomization layers: age, sex, disease severity Randomization tool: A sealed envelope containing the number of blocks How to build a sequential image: based on blocks with size of 4 and 6 .

**Blinding (investigator's opinion)**

Not blinded

**Blinding description****Placebo**

Not used

**Assignment**

Parallel

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Research Ethics Committee of Baqiyatallah University of Medical Sciences

**Street address**

Mollasadra-south Shikh bahaei

**City**

Tehran

**Province**

Tehran

**Postal code**

1939-55487

**Approval date**

2020-10-12, 1399/07/21

**Ethics committee reference number**

IR.BMSU.REC.1399.400

**Health conditions studied****1****Description of health condition studied**

COVID-19

**ICD-10 code**

U07.1

**ICD-10 code description**

COVID-19, virus identified

**Primary outcomes****1****Description**

hospitalization time

**Timepoint**

Before starting the study and after 5 days of using herbal supplements

**Method of measurement**

A researcher-made questionnaire whose validity and reliability have been assessed

**Secondary outcomes**

empty

**Intervention groups****1****Description**

Intervention group: The drug (including tea, honey and royal jelly for 5 days) is delivered to the hospital along with the list of codes of patients in the intervention group (to be presented to patients in the intervention group). The composition inside each CRSM-X7 tea bag includes 10 grams of marshmallow, 5 grams of Sweet violet, 5 grams of Wild mallow, 5 grams of Damask rose, 10 grams of Liquorice root. After identification and registration, they will be placed in special bags for use. Each bag of CRSM-X7 herbal tea is infused in a volume of

300 ml of boiling water for one day use. After the temperature of the drink is reduced (it reached the temperature of 40 ° C), 5 cc of lavender honey is added, dissolved in it and drunk. So that, three glasses (each glass is equivalent to 100 ml) will be drunk per day (half an hour before breakfast, one hour before lunch, one hour before bedtime) up to five days by the intervention group. The seventh element of this supplement is Royal Jelly, which is prepared in the proportion of 50 grams of Royal Jelly in one kilo gram of lavender honey and should be used by the people under study 4 meals a day, ie morning, noon, evening, night for 5 days (each Promise of 2.5 cc).

**Category**

Treatment - Other

**2****Description**

Control group: Control group: 92 people are in the control group, which includes other patients and hospitalized in the same treatment center who receive a standard treatment regimen similar to the intervention group.

**Category**

Treatment - Other

**Recruitment centers****1****Recruitment center****Name of recruitment center**

Baqiyatallah Hospital

**Full name of responsible person**

Mohammad Ali Abyazi Haris

**Street address**

Mollasadra-South Sheikh bahaei

**City**

Tehran

**Province**

Tehran

**Postal code**

1939-55487

**Phone**

+98 21 8861 4523

**Email**

yashar862@gmail.com

**Sponsors / Funding sources****1****Sponsor****Name of organization / entity**

Bagheiat-allah University of Medical Sciences

**Full name of responsible person**

Ahmad-Reza Sharifi Alvan Abadi

**Street address**

Mollasadra-South sheikh bahaei

**City**

Tehran

**Province**

Tehran

**Postal code**

1939-55487

**Phone**

+98 21 8861 4523

**Email**

sharifiahmaddr@gmail.com

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

No

**Title of funding source**

Iranian Matin Gene Co.

**Proportion provided by this source**

100

**Public or private sector**

Private

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

*empty*

**Country of origin****Type of organization providing the funding**

Persons

**Person responsible for general inquiries****Contact****Name of organization / entity**

Bagheiat-allah University of Medical Sciences

**Full name of responsible person**

Ahmad-Reza Sharifi Alvan Abadi

**Position**

Faculty Member

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Traditional Medicine

**Street address**

Mollasadra- south Sheikh Bahaei

**City**

Tehran

**Province**

Tehran

**Postal code**

1939-55487

**Phone**

+98 21 8861 4523

**Email**

sharifiahmaddr@gmail.com

**Person responsible for scientific inquiries****Contact****Name of organization / entity**

Bagheiat-allah University of Medical Sciences

**Full name of responsible person**

Ahmad-Reza Sharifi Alvan Abadi

**Position**

Faculty Member

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Traditional Medicine

**Street address**

Mollasadra- south Sheikh Bahaei

**City**

Tehran

**Province**

Tehran

**Postal code**

1939-55487

**Phone**

+98 21 8861 4523

**Email**

sharifiahmaddr@gmail.com

**Person responsible for updating data**

**Contact**

**Name of organization / entity**

Bagheiat-allah University of Medical Sciences

**Full name of responsible person**

Mohammad Heiat

**Position**

Assistant professor

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Internal Medicine

**Street address**

Vanak sq. Mollasadra st. Baqiyatallah University of Medical Sciences, Tehran, Iran

**City**

Tehran

**Province**

Tehran

**Postal code**

1939-55487

**Phone**

+98 21 8861 4523

**Fax**

**Email**

Mohamad.heiat@bmsu.ac.ir

**Sharing plan**

**Deidentified Individual Participant Data Set (IPD)**

Yes - There is a plan to make this available

**Study Protocol**

Yes - There is a plan to make this available

**Statistical Analysis Plan**

Yes - There is a plan to make this available

**Informed Consent Form**

Yes - There is a plan to make this available

**Clinical Study Report**

Yes - There is a plan to make this available

**Analytic Code**

Yes - There is a plan to make this available

**Data Dictionary**

Not applicable

**Title and more details about the data/document**

All study documents which includes the variables studied in the study will be shared and made available after the publication of the article, without any conditions.

**When the data will become available and for how long**

The access period will start after the article is published in a scientific journal

**To whom data/document is available**

All people, including researchers working in academic and scientific institutions, or people working in industry, will be able to access the data.

**Under which criteria data/document could be used**

Once the article has been published in an international journal, there are no preconditions for accessing the data to perform any type of analysis on the delivered data.

**From where data/document is obtainable**

Baqiyatallah University of Medical Sciences, Traditional Medicine Research Center / Gastroenterology and Liver Research Center

**What processes are involved for a request to access data/document**

After the data is published in an international journal, information will be provided with a simple, basic written request without any formalities.

Mohamad.heiat@gmail.com

**Comments**